Kaleido Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	2016
Period Ending	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	2016
Revenue	1.1	0.98	-	-	-	Upgrade
Revenue Growth (YoY)	13.23%	-	-	-	-	Upgrade
Cost of Revenue	67.8	55.97	64.23	-	-	Upgrade
Gross Profit	-66.7	-54.99	-64.23	-	-	Upgrade
Selling, General & Admin	20.97	23.88	22.43	18.62	6.04	Upgrade
Research & Development	-	-	-	42.06	20.99	Upgrade
Other Operating Expenses	-0.15	0.19	-	-	-	Upgrade
Operating Expenses	20.82	24.08	22.43	60.68	27.03	Upgrade
Operating Income	-87.52	-79.07	-86.66	-60.68	-27.03	Upgrade
Interest Expense	-2.84	-2.8	-0.98	-1.01	-0.44	Upgrade
Interest & Investment Income	0.07	0.25	1.69	1.12	0.03	Upgrade
Other Non Operating Income (Expenses)	-	-	0.19	-1.17	-0.13	Upgrade
EBT Excluding Unusual Items	-90.29	-81.62	-85.75	-61.74	-27.56	Upgrade
Other Unusual Items	-	-	-0.58	-	-	Upgrade
Pretax Income	-90.29	-81.62	-86.33	-61.74	-27.56	Upgrade
Net Income	-90.29	-81.62	-86.33	-61.74	-27.56	Upgrade
Net Income to Common	-90.29	-81.62	-86.33	-61.74	-27.56	Upgrade
Shares Outstanding (Basic)	42	33	26	5	4	Upgrade
Shares Outstanding (Diluted)	42	33	26	5	4	Upgrade
Shares Change (YoY)	25.14%	30.14%	403.18%	14.29%	19.13%	Upgrade
EPS (Basic)	-2.16	-2.44	-3.36	-12.09	-6.17	Upgrade
EPS (Diluted)	-2.16	-2.44	-3.36	-12.09	-6.17	Upgrade
Free Cash Flow	-78.22	-65.54	-79.38	-49.32	-23.9	Upgrade
Free Cash Flow Per Share	-1.87	-1.96	-3.09	-9.65	-5.35	Upgrade
Operating Margin	-7927.72%	-8109.44%	-	-	-	Upgrade
Profit Margin	-8178.26%	-8371.28%	-	-	-	Upgrade
Free Cash Flow Margin	-7085.42%	-6722.26%	-	-	-	Upgrade
EBITDA	-85.16	-77.24	-85.34	-59.89	-26.71	Upgrade
D&A For EBITDA	2.36	1.82	1.32	0.79	0.32	Upgrade
EBIT	-87.52	-79.07	-86.66	-60.68	-27.03	Upgrade

Updated Apr 1, 2022. Source: S&P Global Market Intelligence. Standard template. Financial Sources.